Intraperitoneal Floxuridine in Gastric Carcinoma
Dose of intraperitoneal FUDR 3000 mg/day x 3 days per cycle (2 cycles total, 2 weeks apart)
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Safety of intraperitoneal FUDR
This protocol is testing the safety of giving two cycles of intraperitoneal FUDR followed by the conventional postoperative chemo-radiation for gastric cancer
three months after surgery
Yes
United States: Food and Drug Administration
2150
NCT00058916
September 2002
December 2009
Name | Location |
---|---|
New York University School of Medicine | New York, New York 10016 |
University of Southern California | Los Angeles, California 90033 |